BioHaven
Biohaven begins a clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some cases can be fatal in COVID-19
Rankings by 
Национальный рейтинг
282nd
in United StatesРегиональный рейтинг
316th
in North America and CaribbeanГлобальный рейтинг
773rd
worldwide